371 related articles for article (PubMed ID: 32222129)
1. Tuberous sclerosis: a review of the past, present, and future.
Uysal SP; Şahin M
Turk J Med Sci; 2020 Nov; 50(SI-2):1665-1676. PubMed ID: 32222129
[TBL] [Abstract][Full Text] [Related]
2. [Tuberous sclerosis complex: A review].
Pfirmann P; Combe C; Rigothier C
Rev Med Interne; 2021 Oct; 42(10):714-721. PubMed ID: 33836894
[TBL] [Abstract][Full Text] [Related]
3. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
4. [Neuropsychiatric manifestations in Tuberous Sclerosis Complex (TSC): diagnostic guidelines, TAND concept and therapy with mTOR inhibitors].
Waltereit R; Feucht M; de Vries MC; Huemer J; Roessner V; de Vries PJ
Z Kinder Jugendpsychiatr Psychother; 2019 Mar; 47(2):139-153. PubMed ID: 30080117
[TBL] [Abstract][Full Text] [Related]
5. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
6. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
7. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
8. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
9. Tuberous Sclerosis Complex (TSC) Inactivation Increases Neuronal Network Activity by Enhancing Ca
Hisatsune C; Shimada T; Miyamoto A; Lee A; Yamagata K
J Neurosci; 2021 Sep; 41(39):8134-8149. PubMed ID: 34417327
[TBL] [Abstract][Full Text] [Related]
10. Tuberous sclerosis complex.
Islam MP; Roach ES
Handb Clin Neurol; 2015; 132():97-109. PubMed ID: 26564073
[TBL] [Abstract][Full Text] [Related]
11. Revisiting Brain Tuberous Sclerosis Complex in Rat and Human: Shared Molecular and Cellular Pathology Leads to Distinct Neurophysiological and Behavioral Phenotypes.
Kútna V; O'Leary VB; Newman E; Hoschl C; Ovsepian SV
Neurotherapeutics; 2021 Apr; 18(2):845-858. PubMed ID: 33398801
[TBL] [Abstract][Full Text] [Related]
12. Incidental diagnosis of tuberous sclerosis complex by exome sequencing in three families with subclinical findings.
Caylor RC; Grote L; Thiffault I; Farrow EG; Willig L; Soden S; Amudhavalli SM; Nopper AJ; Horii KA; Fleming E; Jenkins J; Welsh H; Ilyas M; Engleman K; Abdelmoity A; Saunders CJ
Neurogenetics; 2018 Aug; 19(3):205-213. PubMed ID: 29926239
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND).
Gipson TT; Johnston MV
F1000Res; 2017; 6():. PubMed ID: 28663780
[TBL] [Abstract][Full Text] [Related]
14. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
15. Genetics, genomics, and genotype-phenotype correlations of TSC: Insights for clinical practice.
Peron A; Au KS; Northrup H
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):281-290. PubMed ID: 30255984
[TBL] [Abstract][Full Text] [Related]
16. A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex.
Li X; Hu T; Liu J; Fang B; Geng X; Xiong Q; Zhang L; Jin Y; Liu X; Li L; Wang Y; Li R; Bai X; Yang H; Dai Y
J Genet Genomics; 2020 Dec; 47(12):735-742. PubMed ID: 33612456
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system manifestations of tuberous sclerosis complex.
Lu DS; Karas PJ; Krueger DA; Weiner HL
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):291-298. PubMed ID: 30230171
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
19. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.
de Vries PJ; Belousova E; Benedik MP; Carter T; Cottin V; Curatolo P; Dahlin M; D'Amato L; d'Augères GB; Ferreira JC; Feucht M; Fladrowski C; Hertzberg C; Jozwiak S; Kingswood JC; Lawson JA; Macaya A; Marques R; Nabbout R; O'Callaghan F; Qin J; Sander V; Sauter M; Shah S; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2018 Sep; 13(1):157. PubMed ID: 30201051
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]